NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Study population consists in patients with a diagnosis of mCRC who have never received systemic treatment for advanced/metastatic disease and who are candidate to receive a first line therapy with FOLFIRI plus cetuximab or bevacizumab
1 total trials1 recruiting
Filter these 1 trials by phase, country, sponsor and more.